Biomarkers Dementia Diabetes 
Dr. Paddy Barrett
FEBRUARY 21, 2025
The reason excess weight is such big issues are the health consequences it confers with increased rates of diabetes, heart disease, osteoarthritis, obstructive sleep apnea, non-alcoholic fatty liver disease and others, just to name a few. Avoiding diabetes and its precursor states inclduing insulin resistance is key. Nat Med (2024).
Dr. Paddy Barrett
OCTOBER 11, 2024
I have covered this topic previously here , but it is clear that inflammation plays a major role in the initiation and progression of coronary artery disease, and the inflammatory biomarker hsCRP is tightly connected to this process. Dementia is a leading cause of death and a major concern for most people as they age. N Engl J Med.
Dr. Paddy Barrett
SEPTEMBER 13, 2024
Everyone sits somewhere on the scale of insulin sensitivity from very insulin sensitive to very insulin resistant at the point of type 2 diabetes. Understanding where you sit on this continuum is a key part of defining your future risk of heart disease but also dementia, and many cancers. Measuring Insulin Resistance. Some complex.
Stroke Journal
JANUARY 30, 2025
They are key indicators of cerebral small vessel disease (CSVD) and are associated with mild cognitive impairment (MCI) and dementia. Multiple linear regression models tested associations between PVS burden and each NP test, adjusting for age, sex, smoking, diabetes, hypertension, and education.Results:Among 3777 participants (mean age 60.6
Stroke Journal
FEBRUARY 1, 2024
Introduction:The Neurofilament light chain (NfL) is a neuronal cytoplasmic protein and a reliable biomarker for assessing axonal damage in neurological diseases and traumatic brain injury. Asymptomatic intracranial large artery stenosis (ILAS) has been associated with higher risk of stroke and dementia.
Dr. Malcolm Kendrick
OCTOBER 30, 2024
(2022-25) Swiss Reinsurance Company: £645K China Kadoorie Biobank (2002-ongoing) AstraZeneca: $300K Bayer AG: £300K GlaxoSmithKline: £3.6M Elinogrel feasibility trial (2010-2011) Novartis: £500K EMPA-KIDNEY (2017-ongoing) Boehringer Ingelheim: £106.3M Establishing Fuwai-Oxford research centre (2010-ongoing) Merck: £1.1M
Dr. Smith's ECG Blog
FEBRUARY 26, 2025
Written by Magnus Nossen, edits by Smith The patient in today's case is an 85-year-old male with a history of COPD and dementia. Due to very severe dementia, it was impossible to obtain a detailed history. He presented to the emergency department for evaluation. Lets us consider two different clinical presentations.
Expert insights. Personalized for you.
80 
Let's personalize your content